Clinical profiling of AML1::ETO and KIT exon 17 mutation in pediatric AML by high-throughput drug sensitivity

Zhilin Hu, Xue Tang, Fen Chen, Tonghui Li, Yi Liu, Guichi Zhou, Qian Li, Shilin Liu, Ying Wang, Feiqiu Wen, Huirong Mai, Lulu Wang, Sixi Liu · 2026

Read Clinical profiling of AML1::ETO and KIT exon 17 mutation in pediatric AML by high-throughput drug sensitivity by Zhilin Hu, Xue Tang, Fen Chen, Tonghui Li, Yi Liu, Guichi Zhou, Qian Li, Shilin Liu, Ying Wang, Feiqiu Wen, Huirong Mai, Lulu Wang, Sixi Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13628913.txt.

Description

Zhilin Hu and twelve colleagues asked why a usually mild childhood leukaemia sometimes turns risky. The danger comes when a second mutation is present. Their 2026 study concerns leukaemia carrying the AML1-ETO fusion. It asks what a matching KIT mutation in exon 17 does to outlook and drug response.

The team mined a database of 957 child patients. The exon 17 mutation largely wiped out the fusion type's survival edge. Tests on marrow samples from sixteen patients in Shenzhen hinted at broad drug resistance. Standard chemotherapy drugs seemed to fail against it. Gene activity pointed to one gene, SOCS1, switched up in the resistant pattern. The authors argue for finer risk grouping by KIT profile. They also urge study of the linked signalling axis as a treatment target.

Catalog record

CREATORZhilin Hu, Xue Tang, Fen Chen, Tonghui Li, Yi Liu, Guichi Zhou, Qian Li, Shilin Liu, Ying Wang, Feiqiu Wen, Huirong Mai, Lulu Wang, Sixi Liu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49731
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13628913

Browse the full library · About the Tower of Babel